Medication Risk
A claimant on a stable regimen develops fatigue, dizziness, low mood, constipation or a new pain. The treating doctor adds a diagnosis and a medication. In a meaningful share of cases the new symptom was caused by a drug already on the claim, and the claim has just funded the treatment of a side effect as if it were a disease.
Why do adverse drug effects get mistaken for new conditions?
Adverse drug reactions rarely announce themselves. They present as ordinary symptoms: tiredness, dizziness, nausea, swollen ankles, poor sleep, low mood, foggy thinking, a dry mouth, a cough. Every one of those has a dozen non-drug explanations, and a busy consultation defaults to the most familiar one. Australian Prescriber has described the result for more than a decade: a new medicine is prescribed to treat an adverse reaction to another medicine, in the mistaken belief that a new medical condition is present. That pattern has a name, the prescribing cascade, and it is one of the most reliable ways a personal injury claim grows.
Three features of adverse effects make the error easy. The timing is often delayed, with symptoms appearing weeks or months after a dose change rather than the next day. The presentation overlaps with the injury itself, so pain, poor sleep and low mood from an opioid or a gabapentinoid look exactly like pain, poor sleep and low mood from a back injury. And the effect is cumulative: an anticholinergic load built from three individually modest medications produces constipation, confusion and urinary retention that no single prescriber sees as their drug's fault.
How common is this in practice?
Australian data on adverse drug events in general practice suggest roughly one in ten patients experiences one within six months, with adverse medicine events contributing to more than 190,000 hospital admissions a year. Population studies of prescribing cascades are more specific. A 2024 Ontario cohort of 39,347 older adults with hypertension found that 4.8 per cent were started on a diuretic within 90 days of starting a calcium channel blocker, almost certainly to treat drug-induced ankle swelling, and that group had a 21 per cent higher rate of serious adverse events than patients who were not cascaded. A 2025 Irish study of more than 533,000 community-dwelling adults over 65 found several cascades directly relevant to injury claims: antidepressant to sleeping tablet, benzodiazepine to antipsychotic, and antipsychotic to anti-parkinsonian drug.
Injured workers are younger than those cohorts but their regimens look similar. A 2026 Monash analysis in the British Journal of Clinical Pharmacology examined psychotropic dispensing in Australian workers with compensation claims for back and neck conditions and found antidepressant, benzodiazepine and gabapentinoid use rising after injury. Each of those classes is a documented source of symptoms that get relabelled as something new.
What are the five questions that separate a side effect from a diagnosis?
Pharmacovigilance has used the same causality logic for 45 years, formalised in the Naranjo scale. A claims manager does not need the scoring, only the questions behind it.
| Question | What points to a drug effect | What points to a genuine new condition |
|---|---|---|
| Timing: when did the symptom start relative to any medication start, dose increase or new addition? | Onset within days to a few months of a change; onset after a dose escalation | Onset with no medication change in the preceding months |
| Plausibility: is this a known effect of anything on the list? | The symptom appears in the product information for a current medication, or matches the class (sedation, anticholinergic, serotonergic) | No current medication is associated with the symptom |
| Dechallenge: what happened when the drug was reduced, paused or stopped? | Symptom improved or resolved | Symptom persisted unchanged, or the drug has never been reduced so nobody knows |
| Rechallenge: did the symptom return when the drug was restarted or the dose went back up? | Yes, on a similar timeline | No recurrence |
| Alternatives: has the obvious non-drug cause actually been excluded? | Investigations for the "new condition" are normal or were never done | Imaging, pathology or specialist assessment confirm an independent cause |
The dechallenge question is the one that matters most and the one least often asked. In a cascade, the drug is never stopped because the new symptom has already been given a new name. Once "drug-induced oedema" becomes "peripheral oedema, query cardiac" the calcium channel blocker is safe from scrutiny and a diuretic is on its way.
Which symptoms on a claim should trigger the question?
The symptoms most often relabelled on personal injury claims cluster around the drug classes most often prescribed on them. Sedation, fatigue and cognitive slowing are attributed to depression, sleep disorder or "post-concussion" when opioids, gabapentinoids, benzodiazepines and sedating antidepressants are on the list. Dizziness and falls are attributed to vestibular or cardiac causes when the same drugs, plus antihypertensives, are present. Constipation, reflux and abdominal pain are investigated as gastrointestinal disease when opioids are the driver. Low mood, irritability and anxiety are diagnosed as a secondary psychological injury when they emerged after a sedative or opioid escalation. New or worsening pain is treated as progression when opioid-induced hyperalgesia or statin myalgia is the better fit. Each of these is covered in detail in the companion reference on side effects mistaken for new conditions.
What does this mean for liability and claim cost?
A new diagnosis added mid-claim carries three costs. The first is direct: the new medication, the investigations, the specialist. The second is duration: a claimant now being treated for two or three conditions is further from work capacity than one being treated for one. The third is liability. If the "new condition" is accepted as a consequence of the compensable injury or its treatment, it becomes a secondary injury with its own entitlement stream. NSW psychological injury claims illustrate the scale: 12 per cent of claims but 38 per cent of cost, with an average claim cost of $288,542 in 2024-25. Some of those secondary psychological injuries are pharmacological in origin, and a drug-induced depression that would have resolved on dose reduction is a different liability question from a psychiatric injury that requires years of treatment. That distinction is examined in the article on medication-induced psychological symptoms.
The insurer cannot direct prescribing. What it can do is decline to fund a second diagnosis until the first explanation has been tested, and ask a defined set of questions before approving a new treatment line. The practical test is simple: has anyone documented that the current medications were considered as the cause, and has anyone tried reducing the likeliest culprit?
What should a claims manager do with a suspected drug-induced symptom?
Request the current full medication list, including over-the-counter and complementary products, and the dates of every start and dose change in the preceding six months. Line those dates up against the symptom onset. If a plausible drug precedes the symptom, ask the treating practitioner in writing whether the medication has been considered as a cause and whether a supervised dose reduction is appropriate before further investigation or new treatment is funded. Where the regimen is complex or the treating practitioner disagrees, refer for an independent clinical pharmacy review. A pharmacist's report gives the claims manager a causality assessment in plain language, a recommended sequence for testing the hypothesis, and a defensible basis for the funding decision either way. The full mechanism, and how to interrupt it, is set out in the article on prescribing cascades in personal injury claims.
Key Takeaways
- A new symptom on a claim is frequently an adverse effect of a medication already being funded, not a new condition.
- The mechanism is the prescribing cascade: a side effect is misread as a disease and treated with a second drug, which brings its own side effects.
- Five questions separate the two: timing, plausibility, dechallenge, rechallenge and exclusion of alternatives. Dechallenge is the one most often skipped.
- Sedation, dizziness, constipation, low mood and new pain are the symptoms most often relabelled on personal injury claims, and opioids, gabapentinoids, benzodiazepines and antidepressants are the usual sources.
- A relabelled side effect adds treatment cost, extends duration and can become a secondary injury with its own liability stream.
- Before funding a new diagnosis mid-claim, ask whether the current medications have been considered as the cause and whether a supervised reduction has been tried.
Frequently Asked Questions
Can a medication side effect appear months after starting the drug?
Yes. Some adverse effects are immediate, but many emerge after weeks or months as tolerance, accumulation or dose escalation set in. Opioid-induced constipation and hyperalgesia, gabapentinoid cognitive effects and antidepressant-related sleep disturbance all commonly appear well after initiation, which is exactly why they are attributed to something else.
What is a prescribing cascade?
A prescribing cascade occurs when an adverse effect of one medicine is misinterpreted as a new medical condition and a second medicine is prescribed to treat it. The second drug adds cost and its own adverse effects while the original cause continues untreated. The term was introduced by Rochon and Gurwitz in 1997 and is now a recognised marker of avoidable medication harm.
How does a claims manager check whether a symptom is drug-induced?
Line up the dates of every medication start and dose change against the symptom onset, check whether the symptom is a known effect of anything on the list, and ask whether the likely culprit has ever been reduced to see if the symptom improves. If those questions have not been answered in the file, they should be answered before a new treatment line is funded.
Should the insurer fund treatment for a suspected drug-induced condition?
Funding decisions are made on whether treatment is reasonably necessary. Treatment for a symptom that would resolve on dose reduction of an existing funded medication is difficult to justify as reasonably necessary until that reduction has been tried. An independent clinical pharmacy review provides the evidence to make and defend that call.
Primary sources: Kalisch, Caughey, Roughead and Gilbert, The prescribing cascade, Australian Prescriber 2011; Rochon and Gurwitz, The prescribing cascade revisited, Lancet 2017; Rochon et al, calcium channel blocker and diuretic prescribing cascade cohort, Journal of the American Geriatrics Society 2024; Prescribing cascades among older community-dwelling adults, Annals of Family Medicine 2025; Tefera et al, psychotropic medicine utilisation in Australian workers with compensation claims, British Journal of Clinical Pharmacology 2026; Naranjo et al, adverse drug reaction probability scale, 1981; NSW workers compensation reform data, 2026.
